Search Results
Your search for it matches 15610 pages
Showing 2401 - 2450Patients With Multiple Myeloma May Face CAR T-Cell Shortages
From microchips to automobiles, people in the United States are experiencing shortages of all kinds of products, and oncology treatments are no exception. In particular, shortages related to chimeric antigen receptor (CAR) T-cell therapy have been reported, most acutely, for B-cell maturation...
Trastuzumab Deruxtecan for Advanced HER2-Mutant NSCLC
On August 11, 2022, fam-trastuzumab deruxtecan-nxki was granted accelerated approval for unresectable or metastatic non–small cell lung cancer (NSCLC) with tumors that have activating HER2 mutations, as detected by a U.S. Food and Drug Administration (FDA)-approved test and who have received a...
Capmatinib for Metastatic NSCLC With MET Exon 14 Skipping Mutation
On August 10, 2022, capmatinib was granted regular approval for patients with metastatic non–small cell lung cancer (NSCLC) with tumors having a mutation leading to mesenchymal-epithelial transition (MET) exon 14 skipping, as detected by a U.S. Food and Drug Administration–approved test.1...
Practice-Changing Studies, Important New Data, and More Clinical Oncology News From ESMO 2022, Paris
The European Society For Medical Oncology (ESMO) launched its annual congress, held September 9–13, 2022, just as this issue of The ASCO Post was going to press. Watch upcoming issues for comprehensive coverage of the live congress, following 2 years of virtual meetings and remote presentations due ...
Expert Point of View: Benjamin Besse, MD, PhD
Discussant of the IMpower010 abstract, Benjamin Besse, MD, PhD, Professor and Head of Clinical Research at Institute Gustave Roussy, Villejuif, France, said there is enough evidence to use adjuvant immunotherapy in stage II–IIIA resected non–small cell lung cancer (NSCLC), calling the increased...
What the Supreme Court’s Abortion Decision Means for Patients With Cancer and Their Clinicians
On June 24, 2022, the Supreme Court ruled in Dobbs v Jackson Women’s Health Organization (Dobbs)1 and overturned Roe v Wade and Planned Parenthood v Casey, which recognized a federal constitutional right to end a pregnancy up to the point of viability. This decision opened the door for states to...
Is Germline Testing Warranted for All Patients With Lung Cancer?
Germline testing may be warranted for all patients with lung cancer, according to research presented during the August 2022 ASCO Plenary Series by Renato G. Martins, MD, MPH, Chair of Hematology Oncology and Palliative Care at Virginia Commonwealth University Massey Cancer Center, Richmond.1 The...
Expert Point of View: Corinne Faivre-Finn, MD, PhD and Masahiro Tsuboi, MD
The first discussant of the NADIM II study, Corinne Faivre-Finn, MD, PhD, Professor of Thoracic Radiation Oncology, University of Manchester, and Honorary Consultant Clinical Oncologist at The Christie NHS Foundation Trust, Manchester, England, called the results “very impressive” but noted that...
AACR Cancer Progress Report 2022 Shows Cancer Mortality Rates Continue to Decline, but Challenges Remain
Advances in more effective treatment and early detection diagnostics, coupled with reductions in smoking rates, have resulted in a 32% decline in cancer mortality in the United States since 1991, translating into nearly 3.5 million lives saved, according to the newly released American Association...
Study Shows Many Patients Prefer Stool Test to Colonoscopy for Colorectal Cancer Screening
Three-quarters of surveyed people preferred to do a fecal immunochemical test (FIT) rather than undergo a colonoscopy for their regular colorectal cancer screening, according to a new Cedars-Sinai study published by Makaroff et al in Clinical Gastroenterology and Hepatology. “One of the big issues...
Precision Physical Activity Prescriptions May Improve Survival in Patients With Stage III Colon Cancer
Physical activity may be associated with improved outcomes for patients undergoing postoperative treatment for stage III colon cancer, according to findings from a new study out of Pennington Biomedical Research Center published by Brown et al in the Journal of Clinical Oncology. The study assessed ...
New, Long-Term Opioid Use After Lung Cancer Surgery Linked to Reduced 2-Year Survival
New, long-term use of opioids after lung cancer surgery was linked to a 40% increased risk of death from any cause within the following 2 years, according to findings published by Oh et al in the journal Regional Anesthesia & Pain Medicine. Persistent postoperative pain has been reported in up...
Adjuvant Pembrolizumab in Patients With Completely Resected Stage IB to IIIA NSCLC
As reported in The Lancet Oncology by O’Brien et al, the second interim analysis of the phase III PEARLS/KEYNOTE-091 trial has shown significantly improved disease-free survival with adjuvant pembrolizumab vs placebo in patients with completely resected stage IB to IIIA non-small cell lung cancer...
New Imaging Technique May Improve Accuracy of Basal Cell Carcinoma Diagnosis
A novel imaging technique may significantly improve the accuracy of the diagnosis of basal cell carcinoma (BCC) compared to clinical and dermoscopic examinations alone, according to new research presented at the 31st European Academy of Dermatology and Venereology (EADV) Congress. The study found...
Housing Instability and Risk of Mortality in Patients With Cancer
Little is known about patients with cancer’s social welfare and how it affects their health outcomes. To address this, researchers at University of California (UC) San Diego School of Medicine and partnering institutions assessed the prevalence and impact of various social risk factors in patients...
Neoadjuvant Atezolizumab May Be Safe, Effective Option for Localized Non–Small Cell Lung Cancer
New data show that the immuno-oncology drug atezolizumab may be a safe and effective treatment for patients with stage IB to IIIB non–small cell lung cancer (NSCLC) prior to surgery, according to a study led by researchers with The Ohio State University Comprehensive Cancer Center–Arthur G. James...
Preclinical Study Finds New Synthetic Lethal Agent Could Be Potential Treatment for Pancreatic Cancer
Researchers at The Marvin and Concetta Greenberg Pancreatic Cancer Institute at Fox Chase Cancer Center have found that a new synthetic lethal agent could be an effective treatment for pancreatic cancers with DNA damage repair (DDR) defects. Igor Astsaturov, MD, PhD, a co-director of the Institute...
Study Finds Cancer Mortality Rates Correlate With Geography as Well as Known Behavioral Risk Factors
Researchers at Case Western Reserve University have found that risk factors historically linked to cancer mortality vary regionally across the lower 48 United States—such that they believe those differences should be considered in developing tailored public-health interventions. Dong et al...
Antibody Response to Three-Dose COVID-19 mRNA-1273 Vaccination Schedule in Immunocompromised Patients With Hematologic Cancers
In a Dutch prospective observational cohort study reported in JAMA Oncology, Haggenburg et al found that a third dose of the COVID-19 mRNA-1273 vaccine increased antibody levels in immunocompromised patients with hematologic cancers overall to levels comparable to those observed in healthy controls ...
Neoadjuvant Endocrine Therapy May Elicit Differential Responses in Black vs White Women With Breast Cancer
Black women treated with neoadjuvant endocrine therapy for breast cancer were more likely to benefit than White women if treated at an earlier disease stage, but less likely to benefit than White women if treated at a later disease stage, according to results presented at the 15th American...
Many Families of Children With Leukemia May Experience Food Insecurity That Is Not Alleviated by Federal Assistance Program
Nearly one in four families of pediatric patients with acute lymphoblastic leukemia (ALL) enrolled in a clinical trial experienced food insecurity, and almost half of the families eligible for the Supplemental Nutrition Assistance Program (SNAP) did not receive benefits. In addition, receiving SNAP ...
National Lung Screening Trial Results Highlight Importance of Lifelong Follow-up
Approximately 6% of patients with stage I to III lung cancer develop a second primary lung cancer within 5 years of their initial diagnosis, according to research presented at the International Association for the Study of Lung Cancer (IASLC) 2022 World Conference on Lung Cancer.1 Analysis of data...
Cost-Effectiveness of Chemotherapy Sequences in Metastatic Breast Cancer According to Prior Therapy Exposure
In a modeling study reported in the Journal of Clinical Oncology, Stephanie B. Wheeler, PhD, MPH, and colleagues identified the most cost-effective sequences of single-agent chemotherapy regimens among patients with endocrine-refractory or triple-negative metastatic breast cancer according to prior ...
Study Explores Link Between Use of Antipsychotic Agents and Increased Breast Cancer Risk
A research team from the Centre for Safe Medication Practice and Research (CSMPR) in the Department of Pharmacology and Pharmacy at the University of Hong Kong (HKUMed) conducted a systematic review and meta-analysis of observational studies with over 2 million individuals and estimated a moderate...
Acquired EGFR Inhibitor Resistance Alterations Identified in ctDNA Analysis in Patients With Refractory Metastatic Colorectal Cancer
In a study reported in the Journal of Clinical Oncology by Topham et al, circulating tumor DNA (ctDNA) analysis indicated significantly increased frequencies of multiple potential EGFR inhibitor resistance alterations among patients with refractory metastatic colorectal cancer with vs without prior ...
ASCO Applauds President Biden’s Leadership in Relaunching the Cancer Moonshot
On September 12, Lori J. Pierce, MD, FASTRO, FASCO, Board Chair of the Association for Clinical Oncology (ASCO), made the following statement: “President John F. Kennedy’s historic speech that inspired our nation and an entire generation of Americans to achieve manned space exploration underscored ...
Neoadjuvant Cemiplimab in Patients With Stage II to IV Cutaneous Squamous Cell Carcinoma
In an international, multicenter phase II clinical trial, 63.3% of patients with stage II to IV cutaneous squamous cell carcinoma saw their tumors nearly or completely eradicated when treated with the anti–PD-1 agent cemiplimab-rwlc before surgery. The results were presented by Gross et al at the...
Research Explores Multicancer Early Detection Blood Testing
Physicians, care providers, and payers may be preparing for a major shift in early cancer detection that will affect almost every stage of cancer diagnosis and treatment. New data supporting the accuracy of multicancer early detection blood testing, presented by Deb Schrag, MD, FASCO, MPH, at the...
SWOG S1801: Neoadjuvant and Adjuvant Pembrolizumab for Patients With Stage IIIB to IV Melanoma
Patients with high-risk melanoma who received the anti–PD-1 therapy pembrolizumab both before and after surgery to remove cancerous tissue had a significantly lower risk of their cancer recurring than similar patients who received the drug only after surgery. These results from a study by the SWOG...
T-DXd for Patients With HER2-Low Metastatic Breast Cancer: Patient-Reported Outcomes
Patients who received fam-trastuzumab deruxtecan-nxki (T-DXd) for HER2-low metastatic breast cancer reported that the treatment maintained their quality of life compared to conventional chemotherapy, according to results presented by Ueno et al at the European Society for Medical Oncology (ESMO)...
M14TIL: Tumor-Infiltrating Lymphocytes for Patients With Advanced Melanoma
A novel treatment strategy with personalized cell therapy significantly improved progression-free survival compared to standard immunotherapy in patients with advanced melanoma, according to results from the phase III M14TIL trial reported by John Haanen, MD, PhD, and colleagues at the European...
Nirogacestat for Progressive Desmoid Tumors: DeFi Trial
Significant improvements in progression-free survival and response rate—combined with reduced symptoms and better quality of life—were reported as outcomes of a new treatment approach for patients with desmoid tumors, benign but locally aggressive and invasive soft-tissue tumors. Through targeting...
COSMIC-313: Cabozantinib, Nivolumab, and Ipilimumab in Previously Untreated Patients With Advanced Renal Cell Carcinoma
A targeted kinase inhibitor added to a two-drug immunotherapy combination slowed the progression of advanced kidney cancer in previously untreated patients, according to research led by Toni K. Choueiri, MD. Dr. Choueiri, who is the Director of the Lank Center for Genitourinary Cancer at...
PROSPER RCC: Neoadjuvant Nivolumab Prior to Nephrectomy Followed by Additional Nivolumab in Patients With Renal Cell Carcinoma
The ECOG-ACRIN Cancer Research Group presented data from PROSPER RCC (EA8143), the first randomized phase III trial of neoadjuvant immunotherapy in patients with kidney cancer, at the European Society for Medical Oncology (ESMO) Congress 2022 (Abstract LBA67). Patients with high-risk renal cell...
Researchers Examine How Air Pollution May Drive Lung Cancer in Never-Smokers
A new mechanism has been identified through which very small pollutant particles in the air may trigger lung cancer in people who have never smoked, paving the way to new prevention approaches and the development of novel therapies, according to late-breaking data reported by Charles Swanton, MBBS, ...
ESMO and EONS Announce Launch of PrEvCan
On September 9, the European Society for Medical Oncology (ESMO), together with the European Oncology Nursing Society (EONS), announced the launch of the Europe-wide “Cancer Prevention Across Europe” campaign (PrEvCan) aimed at reducing the burden of cancer. The announcement was made at the opening ...
BRCA Gene Testing for Men: MSK Launches Cancer Screening Clinic
Perhaps the best known of all cancer predisposition genes are inherited mutations in the genes BRCA1 and BRCA2. They were originally associated with an increased risk of breast and ovarian cancers. Later studies revealed that they also increased the risk of prostate and pancreatic cancers and, in...
An Aggressive Type of Non-Hodgkin Lymphoma Threatened My Life
I was just 31 and about to give birth to my fourth child, Yitzchok, when I received a diagnosis of primary mediastinal large B-cell lymphoma. The news was terrifying and crippling. For months, I had been experiencing shortness of breath, coughing, and a pain in my left shoulder, all of which were...
EQRx Pricing Strategy: Not a Win for Everyone but a Key First Step to Expand Access to Cancer Care
EQRx is an economics professor’s dream company. It is the perfect example of the principle of substitution. EQRx provides quality, lower-cost drugs in high-cost categories that may substitute for the higher-priced options. Although the profit margin for each drug unit is smaller than the...
How EQRx Aims to Reengineer the Health-Care System to Produce More Effective, Less Costly Cancer Drugs
The numbers are dizzying. The costs of cancer care in the United States are rising so fast that by 2030, it is projected the national cancer-attributable costs will total more than $246 billion, up from $183 billion in 2015—a 34% increase.1 And although the total global economic burden of cancer is ...
Neurosurgeon Ashish Shah, MD, Returns to Sylvester to Head Clinical Trials and Translational Research on Brain Tumors
Ashish Shah, MD, has assumed the newly created position of Director of Clinical Trials and Translational Research and principal investigator in the Section of Virology and Immunotherapy at Sylvester Comprehensive Cancer Center’s Brain Tumor Initiative (BTI) at the University of Miami Miller School ...
Reconciliation Bill Focuses on Health-Care Provisions
Update: On August 7, 2022, the Senate passed the Inflation Reduction Act (IRA), a broad climate, tax, and health-care reconciliation bill, with a vote of 51 to 50. During a review of the IRA, the Senate parliamentarian removed provisions from the bill that would have required drug companies to pay...
ASCO Updated Guideline of Biomarkers in Metastatic Breast Cancer Supports PIK3CA, BRCA1/2, PD-L1 Testing
ASCO has issued a new practice guideline update on the use of biomarkers in the management of metastatic breast cancer.1 The updated guideline revisits recommendations from the 2015 guideline and addresses topics that have emerged since then in the move toward personalized medicine in metastatic...
Researchers Find DOPA May Protect Against Melanoma and Identify Potential New Therapeutic Targets to Treat Melanoma
People with light skin tones are far more likely to develop melanoma than people with darker skin tones. This large disparity results from far more than can be explained by the ultraviolet (UV) protective effects of melanin pigment, owing in large part to the melanin precursor...
Report Finds Cancers in Adults Younger Than Age 50 Are on the Rise Globally
Over recent decades, more and more adults under the age of 50 are developing cancer. A recently published study revealed that the incidence of early-onset cancers (those diagnosed before age 50)—including breast, colon, esophageal, kidney, liver, and pancreatic cancers, among others—has...
Wall Street Doesn’t Believe in This Target
March 2, 2009. Just published in the Journal of Clinical Investigation.1 And we even got the cover. Twists and turns of heat shock protein-90 (Hsp90), the chaperone, the evolutionary capacitor. Great name and important cancer target. People smiled when I talked about this at the Hsp90 conference....
V. Craig Jordan, CMG, OBE, PhD, DSc, FMedSci, the ‘Father of Tamoxifen,’ Recounts a Life of Adventure and Science
In 2019, Her Majesty Queen Elizabeth II appointed V. Craig Jordan, CMG, OBE, PhD, DSc, FMedSci, Companion of the Most Distinguished order of St. Michael and St. George (CMG), honoring his extraordinary scientific work in the development of selective estrogen receptor modulators, most notably...
Concurrent Chemoradiation Therapy With Weekly Cisplatin for Locally Advanced Head and Neck Squamous Cell Carcinoma
When combined with radiotherapy as definitive treatment of locally advanced head and neck squamous cell carcinoma, cisplatin at a dose of 40 mg/m2 weekly is noninferior to cisplatin at 100 mg/m2 every 3 weeks, according to the results of the ConCERT trial.1 These findings were presented by Atul...
ASCO Remembers Saul A. Rosenberg, MD, FASCO, ASCO Past President and Pioneer of Hodgkin Lymphoma Treatment
On September 5, 2022, the oncology community lost a pioneer in the treatment of Hodgkin lymphoma, Saul A. Rosenberg, MD, FASCO. Dr. Rosenberg was the Maureen Lyles D’Ambrogio Professor in the School of Medicine, Emeritus, at Stanford University. Together with the late Henry Kaplan, MD, Dr....
Report Finds 'Batwing' Mastopexy May Enable More Women to Undergo Nipple-Sparing Mastectomy
Nipple-sparing techniques can provide better outcomes for women undergoing breast reconstruction after mastectomy, but due to complication risks, these approaches are often not offered to women with sagging or larger breasts. For this group of patients, a “batwing” incision may provide a safer...
